key: cord-0882349-hc9srok5
authors: Selvaraj, Gurudeeban; Kaliamurthi, Satyavani; Peslherbe, Gilles H.; Wei, Dong-Qing
title: Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches
date: 2021-04-06
journal: F1000Res
DOI: 10.12688/f1000research.50850.2
sha: 9f7fa69c18ebc32cf6e1f66c5ce93dd9834486be
doc_id: 882349
cord_uid: hc9srok5

Background: Coronavirus (CoV) is an emerging human pathogen causing severe acute respiratory syndrome (SARS) around the world. Earlier identification of biomarkers for SARS can facilitate detection and reduce the mortality rate of the disease. Thus, by integrated network analysis and structural modeling approach, we aimed to explore the potential drug targets and the candidate drugs for coronavirus medicated SARS. Methods: Differentially expression (DE) analysis of CoV infected host genes (HGs) expression profiles was conducted by using the Limma. Highly integrated DE-CoV-HGs were selected to construct the protein-protein interaction (PPI) network. Results: Using the Walktrap algorithm highly interconnected modules include module 1 (202 nodes); module 2 (126 nodes) and module 3 (121 nodes) modules were retrieved from the PPI network. MYC, HDAC9, NCOA3, CEBPB, VEGFA, BCL3, SMAD3, SMURF1, KLHL12, CBL, ERBB4, and CRKL were identified as potential drug targets (PDTs), which are highly expressed in the human respiratory system after CoV infection. Functional terms growth factor receptor binding, c-type lectin receptor signaling, interleukin-1 mediated signaling, TAP dependent antigen processing and presentation of peptide antigen via MHC class I, stimulatory T cell receptor signaling, and innate immune response signaling pathways, signal transduction and cytokine immune signaling pathways were enriched in the modules. Protein-protein docking results demonstrated the strong binding affinity (-314.57 kcal/mol) of the ERBB4-3cLpro complex which was selected as a drug target. In addition, molecular dynamics simulations indicated the structural stability and flexibility of the ERBB4-3cLpro complex. Further, Wortmannin was proposed as a candidate drug to ERBB4 to control SARS-CoV-2 pathogenesis through inhibit receptor tyrosine kinase-dependent macropinocytosis, MAPK signaling, and NF-kb singling pathways that regulate host cell entry, replication, and modulation of the host immune system. Conclusion: We conclude that CoV drug target “ERBB4” and candidate drug “Wortmannin” provide insights on the possible personalized therapeutics for emerging COVID-19.

Coronavirus (CoV) are the largest group of enveloped and single-stranded-ribonucleic acid (ssRNA) pathogens 1 . The genome of CoV is typically larger (27-33Kb) than all other RNA viruses. Briefly, the genome contains an envelope protein, membrane protein, nucleoprotein, and spike protein which are responsible for capsid formation, assembly of virus particles and entry of the virus particle into the host 2 . The CoVs are zoonotic in nature, i.e. transmitted between animals and humans. There were three unforgettable zoonotic infectious diseases outbreak caused by CoVs recorded in the past two decades. In the 20 th century (2002) (2003) , the foremost epidemic outbreak was originated in China by the severe acute respiratory syndrome (SARS) 3 . Later, in the 21 st century (2012), the next epidemic outbreak happened in Saudi Arabia and the gulf countries with the Middle East respiratory syndrome (MERS) 4 . In December 2019, the third epidemic outbreak was recorded in China, especially from Wuhan city through a novel severe acute respiratory syndrome CoV-2 (SARS-CoV-2) (COVID-19) 5 . Paraskevis et al. (2020) 2 reported that the SARS-CoV-2 full-genome belongs to betacoronavirus, but it differs from the epidemic causing SARS and MERS 6 . Moreover, the SARS-CoV-2 genome exhibits 96.3% similarity with the Bat-SARS viruses like CoVs. Among the various human CoVs (229E, NL63, HKU1, OC43, SARS, and MERS), SARS and MERS caused severe respiratory-related mortality rates of 10% and 37% respectively 7 .

Recently, Huang et al. 8 reported that the most widespread symptoms of COVID-19 patients at the beginning of the disease's condition were respectively fever (98%), cough (76%), fatigue (44%) followed by sputum production (28%), headache (8%), blood-stained mucus (5%) and diarrhea (3%). Moreover, nearly one-fifth (19.2%) of individuals with COVID-19 were asymptomatic 9 . COVID-19 positive cases showing the most common symptoms were cough hyposmia, sputum, and fever respectively 9 . In this current pandemic situation, identification of novel biomarkers, which plays an effective role in prognosis and monitoring the status of the SARS-COV-2 disease condition, is necessary. A high-throughput oligonucleotide microarray profiling has been widely employed in measuring the expression of genes (>1000) level significantly. In addition, microarray facilitates the identification of biomarkers (diagnosis/therapeutic), classification of the disease condition, treatment options, and mechanism of action of the gene involved in pathogenesis 10 . Biomarkers are identified through the determination of DEGs between the control and diseased/infected subjects, conversely finding the proteins that each biomarker is in connection with them, assisting to discover the key pathways related to the mechanism of the disease 11-13 . Many genes were involved in the pathogenesis, which make-up very complicated network systems. Coronavirus and influenza are pathogens causing severe respiratory illness to humans 14 . Recent reports demonstrated that SP110, HERC5, SAMD9L, RTP4, ESPT11 genes were identified to control and improve the immune system and defense mechanism against influenza by network analysis 15 . It has the supremacy to act as biomarkers and targets for pediatric influenza mediated therapy. A recent systematic review by 16 Kermali and his colleagues showed the increased level of biomarkers such as C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, D-dimer, cardiac troponin and renal biomarkers (urea and creatinine) were higher, and low level of lymphocytes and platelet count were recorded in severe complicated COVID-19 patients than non-severe COVID-19 patients' plasma and infected lung tissues.

Thus, the present study aimed to identify modules consists of the highly interconnected genes, which are involved in the pathogenesis of coronavirus medicated respiratory syndrome in humans. Microarray analysis of gene expression profiles is a standard and well-known method to identify potential targets and pathways 17,18 . Initially, we collected the gene expression profiles from the Gene Expression Omnibus (GEO) database. Then, we performed differential expression of CoV infected host genes (DE-CoV-HGs) using the Limma algorithm. The protein-protein interaction (PPI) network was constructed with DE-CoV-HGs and extracted different modules from the network using the Walktrap algorithm. Besides, the potential targets were predicted from the selected modules based on the degree and betweenness centrality measures, and determined their functional and pathway enrichment terms. The possible validation of potential targets interaction with proteins of SARS-CoV-2 was performed using protein-protein docking (PPD) and molecular dynamics (MD) simulations. Further, possible candidate drug for defined potential drug target (PDT) "ERBB4" using Drug Gene Budger. An insight into the study provides possible personalized therapeutic target and candidate drug for coronavirus medicated respiratory syndrome. Figure 1 illustrates the work flow of the study.

The coronavirus infected host gene expression profiles were extracted from the GEO database 19 . Agilent-014850 whole human genome microarray 4x44K G4112F platform was employed to GSE100509, GSE86529, GSE47962, GSE47961, GSE47960, GSE45042, GSE37827 and GSE33267 studies and one study GSE56677 which was performed based on Agilent-039494 SurePrint G3 human GE v2 8x60K microarray 039381 platform was included 20-24 . All the selected studies contain control and CoV infected human lung epithelial cells samples. The samples infected with other viruses were excluded. The sample details of different datasets are indicated in Table 1 .

Using NetworkAnalyst (NA) web interface, the tab-delimited text (.txt) files of selected datasets were given as an input for preprocessing, normalization, and probe identification 25 . Variance stabilizing normalization (VSN) and quantile normalization was applied to reduce false-positive errors and equal distributions of datasets for statistical analysis 26,27 . R package "LIMMA" (Linear models for microarray analysis) of from the Bioconductor project were used to perform differential expression of CoV infected host genes 28 . Log2 transformation, Benjamini and Hochberg and t-test were used to perform normalization and calculate false discovery rate (FDR; p<0.05) of samples 29 .

We constructed the PPI network from identified DE-CoV-HGs using Search tool for retrieval of interacting genes/ proteins (STRING) interactome 30 . The highest confidence interaction score was set to 0.9, which reduces false positive interactions 31 . The random walks (R package "igraph") was used to extract modules based on the Walktrap algorithm from the DE-CoV-HGs interaction network 32 . It runs several short random walks within a group of nodes that are highly connected to detect small modules. From the modules, the hub genes (nodes) were identified using two different centrality measures "degree" and "betweenness" 32 . The degree of the gene is the many connections it has to other genes. Genes with a high degree act as hubs within the network. The betweenness of a gene is the number of paths that pass through it when considering the pair-wise shortest paths between all genes in the network. A node that occurs between two dense clusters will have a high betweenness. In the present study, the PDTs of DE-CoV-HGs were identified based on the degree centrality and betweenness centrality measures.

We have used ClueGO v2.5.3, which is a Cytoscape plugin for function and pathway enrichment analysis of DE-CoV-HGs 33 . A list of PDTs were provided as input into ClueGO with select specific parameters like species such as-Homo sapiens; ID type-Entrez gene ID; enrichment functions -KEGG pathways for the analysis. Each enrichment was calculated based on the Bonferroni method (kappa score 0.96; p > 0.005). ImageGP was employed to visualize the results of functional enrichment analysis.

Structural modeling approach to study host-SARS-CoV-2 proteins interaction and drug-target interaction Preparation of host and SARS-CoV-2 viral receptor. The FASTA sequence of selected proteins namely 3C-like protease (3cLpro), angiotensin I converting enzyme 2 (ACE2), B-cell lymphoma 3 (BCL3), casitas b-lineage lymphoma (CBL), CCAAT enhancer binding protein beta (CEBPB), CRK like proto-oncogene (CRKL), histone deacetylase 9 (HDAC9), Kelch-like protein 12 (KLHL12), v-myc myelocytomatosis viral oncogene (MYC), mothers against decapentaplegic homolog 3 (SMAD3), nucleocapsid protein (Npro), nuclear receptor coactivator 3 (NCOA3), receptor tyrosine-protein kinase erbB-4 (ERBB4), spike protein-receptor binding domain (SRBD), SMAD-specific E3 ubiquitin protein ligase 1 (SMURF1), ubiquitin C (UBC), and vascular endothelial growth factor A (VEGFA) were obtained from Uniprot for protein-protein docking studies (Table 3 ) 34 .

Protein-protein docking. PPD was performed in the HDOCK web-interface using ab initio docking with a fast Fourier transform (FFT) based hierarchical algorithm 35,36 . The FASTA sequence of the selected protein (protein 1 and protein 2) was given as input. The server obtained and chosen one of the highest sequence coverage and similarity and with the highest resolution template automatically from PDB and then, the homology modeling was performed using MODELLER. Then, the corresponding structures constructed by superimposing the modeled protein structure on to the template, where 5,000steps of AMBER MD minimization was also performed to remove severe atomic clashes at the interfaces. The putative binding modes between the protein-1 and protein-2 are systematically samples based on the FFT algorithm. In total 4,392 binding modes are ranked depending on their cluster and binding energy scores. The final complex was selected with RMSD of two binding modes was below a cut off 5Å. RMSD was calculated based on the backbone atoms of the protein 2 36 . . is the generality value set as 1 37 .

The results of the PPD complex with the highest binding affinity were used to prepare input files for MD simulations. Solution builder in the CHARMM-GUI web interface was employed to solvate the complex with TIP3P and neutralized by potassium chloride (KCl) ions at the 0.15 mol-1 concentration under CHARMM36 force field 38,39 . The initial configuration of KCl ions is then estimated using short Monte Carlo simulations (2000 steps) through Coulombic and the van der Waals (vdW) interactions. The solvated complex was simulated by using Nanoscale molecular dynamics (NAMD) 40 . Full system long-range Coulombic interactions were determined by the particle mesh Ewald (PME) method 41 . The integrator parameters time was set to 2 fs/step. The simulations were executed in the constant pressure and temperature (NpT ensemble) with pressure bar (1) and temperature (303 K) through the Langevin dynamics with a damping coefficient of 1/ps. After 9×10 7 steps of minimization, water molecules and ions were equilibrated for 2 ns around proteins, which were restrained using harmonic forces. MD simulation of selected drug target (ERBB4-3cLpro) was started from the last frame of restrained equilibration. The production was carried out for 150 ns.

Identification of possible candidate drug for PDT and molecular docking Drug Gene Budger a web-interface was employed to identify possible candidate drugs or small molecules in LINCS L1000 data that significantly regulated selected drug target (ERBB4) expression based on LIMMA algorithm 42 . While entering the gene symbol of drug target, we could retrieve the following information such as log-transformed fold change, p-value and q-value for each potential small molecule. Small molecules/drugs that are liable for considerable overexpression and under expression of downregulated and upregulated drug target can increase the therapeutic action against COVID-19. The threshold q value was derived from the following equation

Where X is the number of false discoveries and Z is the number of true discoveries. Y=X+Z is the number of rejected null hypotheses. The false discovery rate (FDR) is as follows

is the expected value of Q. The drugs/small molecule have the highest log2FC value was selected for further protein-docking studies. The drug target ERBB4 sequence was retrieved from the Uniprot database (ID: Q15303) for three structure modeling. The protein structure modeling was performed in a Swiss modeling server. The structure of the candidate drug "wortmannin" was retrieved from the ZINC database (ID: ZINC1619592). Then, protein-ligand docking was performed to calculate the binding energy of the docked complex in the Swiss dock web-interface, which was developed based on the EADock dihedral space sampling (DSS) algorithm. The energy functions were calculated using the CHARMM force field. Each docking cluster was the output of 250 different sequential runs. The binding models (BM) having the most favorable energies were calculated by fast analytical continuum treatment of solvation (FACTS) and clustered. Binding modes were estimated through Full fitness and clustered. Then, the Full fitness of the clusters was estimated by averaging 30% of the most favorable effective energy of their elements.

The effective energy calculated by the following formula

Ligand , E intra receptor are the internal energies of ligand and receptor; E inter is interaction energy between the receptor and ligand; σ value (0.0072 kcal/mol); SASA is the solvent accessible surface area. The results were visualized in Maestro Visualizer. All the supporting data associated with this study freely available (http://doi.org/10.5281/zenodo.4458252).

In total, 1,968 DE-CoV-HGs in human lung epithelial cells were obtained from the initial analysis. To obtain better results of biomarker identification, we have selected 315 overexpressed and 112 under expressed DE-CoV-HGs based on the logfold changes -1>log2FC>1. Table 2 illustrates the top 10 DE-CoV-HGs, their description, and their fold change and p value. Modules and potential drug targets identification PPI network was constructed using 427 DE-CoV-HGs (Figure 1a) . The major subnetwork contains 531 edges with an average local clustering coefficient 0.353 and the PPI enrichment p-value was 2.36 ×10-3. Then, using the Walktrap algorithm, 47 modules were retrieved from the subnetwork. Among them, highly interconnected modules includes module 1 (No. of nodes=202; p=5.20×10 -32 ); module 2 (No. of nodes=126; p=1.90×10 -28 ) and module 3 (No. of nodes=121; p=3.13×10 -26 ) was employed to identify the PDTs (Figure 2b-d) . Table 3 demonstrated that list of PDTs identified from different modules based on the degree and betweenness centrality measures. BCL3, CBL, CEBPB, CRKL, HDAC9, KLHL12, MYC, SMAD3, NCOA3, ERBB4, SMURF1, UBC, VEGFA were identified as PDTs which are highly expressed in human cells after CoV infection.

Many important gene ontology terms and pathways were identified from the PPI network namely, cellular response to growth factor stimulus, wound healing as a biological process term; growth factor receptor binding as a molecular function term; and TNF signaling pathway and transcriptional mis-regulation in cancer as a pathway enrichment terms ( Figure 3) . Moreover, the biological process term that is directly or indirectly related to the viral life cycle and human immune system includes RNA polymerase II promoter in response to hypoxia, peptidyl-tyrosine auto-phosphorylation, ERBB2 signaling pathway, anaphase-promoting complex dependent catabolic process, interleukin-1 mediated signaling pathway, TAP dependent antigen processing and presentation of peptide antigen via MHC class I, regulation of cellular amino acid and metabolic process, negative regulation of protein acetylation, negative regulation of gene silencing by miRNA, white fat cell differentiation and histone H4 deacetylation enriched in three different modules. Besides, stimulatory c-type lectin receptor signaling pathway (module 1), regulation of hematopoietic stem cell differentiation, T cell receptor signaling, innate immune response signaling and Fc-epsilon receptor signaling pathway (module 2), lymphocyte co-stimulation (module 3) were highly enriched immunological terms of three different modules ( Figure 4 ). Further, pathways enrichment of modules demonstrated that numerous signal transduction pathways and cytokine immune signaling pathways were illustrated in Figure 5 .

Protein-protein docking interaction. The potential target genes encoding proteins are defined as drug targets to control the pathogenesis of SARS-CoV-2. The drug targets regulated (overexpressed or under-expressed) by SARS-CoV-2 during pathogenesis in the host cytoplasm and different cellular components. Accordingly, PPD of SRBD, 3cLpro, and N-protein of SARS-CoV-2 with proposed drug targets happened by different biological signaling pathways. Thus, we hypothesized, proposed drug targets may control the pathogenesis of SARS-CoV-2 through the respective signaling pathways. The possible molecular interaction of host drug targets with SRBD, 3cLpro, and N-protein of SARS-CoV-2 was determined by PPD method. In the present study, we performed protein-protein rigid-body docking, which treats both proteins as rigid and discovers only six degrees of translational and rotational freedom. It excludes any kind of flexibility. Drug targets include HDAC9, SRBD, SMURF1, SRBD, CBL, ERBB4, BCL3, CEBPB, CRKL, KLHL12, MYC, NCOA3, SMAD3, UBC, and VEGFA were in the human respiratory system, which was possibly able to interact with the S-RBD, 3cLpro, and N -protein of SARS-CoV-2 and regulate the viral pathogenesis through replication and development. PPD binding affinities were illustrated in Table 3 . Among the drug targets, ERBB4 demonstrated showed high binding affinity -260.46, -314.57 and -291.72 kcal/mol with SRBD, 3cLpro and N-protein of SARS-CoV-2 respectively. Thus "ERBB4" was selected as potential drug target and used for candidate drug selection study. Hydrogen bond forming residues between the ERBB4 and SRBD, 3cLpro, and N-protein of SARS-CoV-2 complexes represented in Figure 6 .

MD simulations demonstrated the stability of the ERBB4-3cLpro complex. The structure and dynamic properties of the complex were followed by monitoring the backbone Cα root mean square deviation (RMSD) from the initial structure during the simulation period (150ns). The RMSD of the ERBB4-3cLpro complex gradually increased for the first 95 ns before steadily oscillating around a value of ~0.85 nm, indicative of the ERBB4-3cLpro complex stability over the simulation timescale (Figure 7a ). The root mean square fluctuation (RMSF) reflects the fluctuations in the positions of the ERBB4-3cLpro complex residues. Briefly, notable fluctuations have been observed in the multiple furin-like cysteine-rich domains, a tyrosine kinase domain, and a phosphatidylinositol-3 kinase binding site of ERBB4. However, the other amino acid residues in the PDZ binding domain (amino acid range 400-600) were not deviating more ( Figure 7b ). This indicates the reason for the stable RMSD plot of the ERBB4-3cLpro complex. The strong hydrogen bonding interaction (average ~1.89) between ERBB4 and 3cLpro observed throughout the 150ns of MD simulation (Figure 7c ).

The results of Drug Gene Budger demonstrated that Wortmannin (q-value = 3.31×10 -21 ; log2 Fold change = 2.997; Specificity = 1.09×10 -04 ) was identified as the candidate drug for the proposed target ERBB4. The ERBB4 was downregulated after the coronavirus infection that was then upregulated by the possible use of the Wortmannin as candidate drugs, which may inhibit the pathological cycle and development of SARS-CoV-2 in the human hosts. 30 different protein-ligand cluster of binding modes were obtained after molecular docking. Among them, the binding mode of cluster 1 indicated that the ERBB4-Wortmannin complex has the energy in term of full fitness -2563.6987 kcal/mol and Gibbs free energy ∆G was -7.93 kcal/mol (Figure 8 ).

The discovery of biomarkers from gene-expression profiles as well as key functions in a pathogenic-related pandemic disease like COVID-19 is of consequence for diagnosis, drug development, and monitoring of disease progression. Network analysis provides new insights into the biological and cellular organization. The single gene can be involved in many biological functions and regulated different genes at different times 43 . Thus, biomarkers from gene-expression profiles of coronavirus infected subjects have the potential to be employed as drug-targets for COVID-19. Therefore, the present study aimed to identify drug targets from modules containing highly interconnected potential target genes which involve in the pandemic coronavirus pathogenesis. DEGs analysis demonstrated that 315 overexpressed and 112 under expressed genes between normal and CoV-infected subjects. Besides, the potential target genes namely MYC, HDAC9, NCOA3, CEBPB, VEGFA, BCL3, SMAD3, SMURF1, KLHL12, CBL, ERBB4, and CRKL were identified from Walktrap modules, which are significantly associated with the coronavirus infection. Then, the potential target genes encoding proteins employed as PDTs (receptor) for further analysis. Thus, we discussed the possible association of PDTs with pathogenesis of SARS-CoV-2.

MYC regulates numerous cellular functions including cell activation, differentiation, cell cycle progress, transformation, and apoptosis in virus (HIV, hepatitis C, influenza, and Epstein-Barr virus (EBV)) infected host cells 44-46 . In addition, mutation of MYC can disturb human B cells to proliferate indefinitely 47,48 . Further, influenza A virus infection dysregulates the expression of miRNA-22 and induces CD147 in asthmatics through the MYC transcription factor 49 . Moreover, overexpression of the MYC gene associated with PHACTR3 and E2F4 mutation in NSCLC is considered as a potential biomarker of NSCLC and its specific subtypes 50 . This information suggesting that targeting MYC for COVID-19 or CoV mediated respiratory disease has a potential role in the SARS-CoV-2 pathogenesis. SMAD3 is a transcriptional regulator and plays as a mediator of the cellular signals initiated by the transforming growth factor-beta (TGF-β) superfamily of cytokines, which control proliferation, differentiation, and apoptosis. It is a complex regulator in adipose physiology and the pathogenesis of chronic obstructive pulmonary disease, diabetes, inflammatory disease, and obesity 51,52 . In addition, TGF-β/SMAD3-induced repression of target genes, it required repression of the MYC gene. Moreover, SMAD3 deficiency induces inflammatory abnormal bulge on aortic in angiotensin II-infused animal models through the activation of nitric oxide synthases 53 . This information suggesting that under-expressed SMAD3 in CoV mediated respiratory disease has a prospective role in the pathogenesis of SARS-CoV-2. CBL is a proto-oncogene, encoding one of the ubiquitin ligase protein CBL involving in cell signaling, and causes a mutation in the lung, colon, endometrial adenocarcinoma, cutaneous, and breast cancer 54 . In addition, CBL is a potential gatekeeper of immune activation through its function as a non-redundant negative regulator of immune activation. Further 55 , reported that targeting CBL and lipid rafts have the potential to block Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. Moreover, CBL was identified as modulators of immature dendritic cell (DC) activation. The deficiency of CBL in DC upregulates toll-like receptors and inducing pro-inflammatory cytokines and chemokines 56 . Then, reduced expression of CBL in CD4+T cells is reported in several autoimmune diseases namely asthma, lupus erythematodes, multiple sclerosis, and type 1 diabetes 57 . This information is proposing that overexpressed CBL in CoV infected subjects have a prospective role in the host immunological system.

HDAC9 belongs to class II histone deacetylases, and plays a crucial role in regulating adipocyte and myocyte differentiation, and cardiac muscle development. It generally applies its function in the nucleus, and thus its activity is inhibited due to cytoplasmic retention 58 . In addition, HDAC9 transcription is observed significantly high in CD4+ T-cells from lupus subjects compared with healthy subjects 59 . NCOA3 is a transcriptional coactivator that directly binds different nuclear receptors and stimulates hormone-dependent transcriptional activities. In addition, it plays a central role in the remodeling of chromatin, histone acetyltransferase activity, and NF-kB pathway 60,61 . It is effectively used as a biomarker in breast and hepatocellular cancer 62,63 . VEGFA is a signaling protein produced by different types of cells includes macrophages, tumor cells, platelets, keratinocytes, and renal mesangial cells, which play an active role in endothelial cell functions including the formation of bones, and the angiogenesis and hematopoiesis processes. Moreover, the VEGF-A isoform enhanced the entry of the virus into the host cells through the activation of this Akt pathway 64 . Furthermore, SARS coronavirus can diffuse alveolar damage with changeable degrees of acute edema and hyaline membranes, organization, fibrosis, macrophagic infiltration, multinuclear giant cells, atypical reactive pneumocytes, and vascular injury 65,66 . This literature information suggested that accepting the relationship between coronavirus mediated respiratory disease and VEGF signaling biomarkers will cover the way to design targeted and effective therapeutic approaches for emerging COVID-19. BCL3 is a proto-oncogene that resides in the nucleus and plays a key role in the regulation of inflammatory response through the transcription of genes dependent on the NF-κB. In the context of respiratory syncytial virus (RSV) infection, the BCL-3 changes the status of histone acetylation and transcription factors on activated inflammatory (chemokines) promoters 67 . In another study, the BCL-2 gene was significantly up-regulated in PBMC samples of SARS patients (5 fold) than compared to healthy individuals 68 . BCL-3 prevents the inflammation in injured lungs through pinning-down the emergency granulopoiesis process 69 . The SARS-CoV open reading frame 7a (SARS-CoV-7a) protein participated in various pathogenesis processes including interaction with host protein and inhibiting their synthesis, promoting apoptosis, and activation of p38MAPK in the host system 70 . Further, the overexpression of BcL-xL protein in transected Jurkat T-cells significantly block the induction of apoptosis by SARS-CoV-7a protein 71 .

For the biological process, we determined that cellular response to growth factor stimulus wound healing was the key function of the PPI network. The top five functional terms were RNA polymerase II promoter in response to hypoxia, peptidyl-tyrosine auto-phosphorylation, ERBB2 signaling pathway, anaphase-promoting complex dependent catabolic process, interleukin-1 mediated signaling pathway of the modules. For molecular function, growth factor receptor binding is the major term. Growth factor receptor (GFR) mostly belongs to tyrosine kinase receptors or serine-threonine kinases. The cytoplasmic domain of GFR acts as an enzyme or binds to another protein and forms a complex that acts as an enzyme. In addition, binding of GFR leads to phosphorylation of tyrosine residue and transmitting cell signals within the cell 72 . After, viral infection, the ligand (viral proteins) binds to the GFR through cell signaling, phosphorylation, and rearrangement and activates different downstream signaling that enhances cell survival, proliferation, angiogenesis, and endocytosis 73 . Moreover, a recent report demonstrated that GFR as a potential target for drug repurposing against emerging viral diseases such as COVID-19 74, 75 .

Moreover, we also expected to determine which immunological terms linked with coronavirus pathogenesis; namely stimulatory c-type lectin receptor (CLR) signaling pathway, regulation of hematopoietic stem cell differentiation, T cell receptor signaling, innate immune response signaling, and Fc-epsilon receptor signaling pathway, lymphocyte co-stimulation were highly enriched immunological terms of three different modules. The carbohydrate-recognition domains of CLRs are important pattern recognition receptors to identify viral pathogens and induce antiviral innate immune responses and T helper differentiation 76 . Further, reports suggested that the activation of CLRs and RIG-I-like receptors enhances pro-inflammatory response in MERS coronavirus-infected macrophages 77 .

For KEGG pathways, we identified 12 important pathways that might have an essential role in the pathogenesis and human immune system. Eight different signal transduction pathways include nuclear receptor, MAPK, and WNT signaling pathway, receptor tyrosine kinase, intracellular signaling by second messenger, TGF-β, Notch and Hedgehog signaling pathway; four key cytokine immune signaling pathways namely signaling of interleukins, TNFR2-NF-kB pathway, FLT3, and interferon signaling pathways were identified using the hub-genes. Many studies reported that MAPK, WNT, receptor tyrosine kinase, intracellular signaling by the second messenger, TGF-β, Notch, and Hedgehog signaling pathway regulated in viral pathogenesis 78, 79 . As we stated above, overexpression of HDAC9, NCOA3, KLHL12, CBL, and CRKL and under expression of MYC, CEBPB, VEGFA, BCL3, SMAD3, SMURF1, and ERBB4 may be involved in the regulation of pathways in signal transduction and cytokine immune signaling pathways. It might act as a novel drug target of coronavirus infected patients and plays a key role to improve host immune system.

Many biological functions, like cell signaling, cellular metabolism, enzyme inhibition and antibody-antigen recognition, have essential molecular interaction whether receptor-receptor or receptor-drug interaction. These molecular interactions frequently lead to form protein-protein or protein-drug complexes to carry out molecular functions 80 . Unfortunately, there are insufficient gene expression profiles of SARS-CoV-2 infected patients in the GEO database. Thus, in the present study, we have validated that drug targets identified from SARS-CoV-1 infected patients can have the possible interaction with SRBD, 3cLpro and N-protein of SARS-CoV-2 to define possible drug targets. Understanding the binding mode and affinity between PTs encoded host proteins and target proteins of SARS-CoV-2 requires tertiary structure of these proteins. However, it is generally difficult and expensive to obtain complex structures by nuclear magnetic resonance spectroscopy and X-ray crystallography. Thus, protein-protein docking is an important method for understanding interactions of drug targets with SRBD, 3cLpro and N-protein of SARS-CoV-2. In the present study, the protein-protein docking results demonstrated that drug-targets with three different protein of SARS-CoV-2 showed the highest interaction energies Hydrogen bond forming residues between the protein complexes. Among them, the highly under-expressed gene ERBB4 (Table 3 ) encoding drug target "ERBB4" demonstrated high docking interaction energies -260.46, -314.57 and -291.72 kcal/mol with SRBD, 3cLpro and N-protein of SARS-CoV-2 respectively, which was selected for further candidate drug selection studies.

In the present study, the highly downregulated gene ERBB4 was selected as a drug target to control SARS-CoV-2 infection. Figure 9 illustrates the hypothesized mechanism action of downregulated ERBB4 in SARS-CoV-2 infected cells.

A key receptor tyrosine kinase ERBB4 contains four domains includes multiple furin-like cysteine-rich domains, a tyrosine kinase domain, a phosphatidylinositol-3 kinase binding site, and a PDZ binding domain. Ligands are binding to the ERBB4 which induces different cellular response including alveolarization, alveolar epithelial type 2 cells (AEC2) differentiation, anchoring of cell surface receptor, and morphogenesis via extracellular-signal-regulated kinase pathway 81, 82 . Downregulation of ERBB4 inhibits regular action namely alveolarization, morphogenesis, and AEC2 differentiation. Many proteolytic events allow for the release of ERBB4 cytoplasmic fragments. The downregulation of ERBB4 by the SARS-CoV-2 in ACE2 cells may induce receptor tyrosine kinase-mediated macropinocytosis for the host cell entry. Besides, activation of macropinocytosis can increase non-specific fluid uptake, the pH in the vesicle is not decreased and, in that scenario, SARS-CoV-2 may be recycled to the cell surface. Interestingly, fluid-phase uptake (macropinocytosis and cell-to-cell spread) was reported in murine coronavirus and SARS-CoV infection [83] [84] [85] . Both macropinocytosis and PI3K signaling are directly associated with the progression of the number of tumor cells including pancreatic and lung cancer 86, 87 . Further, growing evidence suggested that PI3K signaling involves the generation of the second messenger lipids and activates Rac-Pak signaling which plays a critical function namely macropinocytosis, mTOR signaling clathrin-mediated endocytosis, and cytoskeletal rearrangements 88, 89 . A recent systematic review by 16 and his colleagues showed the increased level of biomarkers such as C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, D-dimer, cardiac troponin and renal biomarkers were higher in severe complicated COVID-19 patients' plasma and infected lung tissues. Another study reported that low levels of type I and III interferons reduced innate antiviral defenses, which act as driving features of COVID-19 90 . In addition, proteome analysis of SARS-CoV-2 infected hosts demonstrated that proteins involved in translation, splicing, carbon metabolism, proteostasis and nucleic acid metabolism could act as a drug target for SARS-CoV-2 91 . Moreover, Gordon et al. reported 67 druggable targets and repurposed 69 FDA-approved drugs for COVID-19 92 . This information supports the technical concept of the present study which enhances drug repurposing strategy and advances on precision-based therapeutics to COVID-19.

In the present study, we repurposed Wortmannin as a candidate drug that can inhibit PI3K signaling and receptor tyrosine kinase (ERBB4) mediated macropinocytosis, to control virus-cell proliferation and may enhance ERBB4 functions namely alveolarization, morphogenesis, and AEC2 differentiation. Wortmannin is a covalent inhibitor of phosphatidylinositol-3-kinase (PI3K) and related enzymes include the mammalian target of rapamycin (mTOR), DNA-dependent protein kinase catalytic subunit (DNA-PKcs), and mitogen-activated protein kinase (MAPK) 93, 94 . In humans, PI3K activates cell signaling pathways in the head and neck, urinary tract, cervical, ovarian, and lung cancer. Studies reported that the inhibition of PI3K signaling enhances tumor suppression and anti-tumor activity 95 . Besides, Wortmannin is an extensively used cell biology research includes to inhibit cell proliferation, DNA repair, and receptor-mediated endocytosis 96, 97 . This report supported that the repurposed Wortmannin may have the potential to control SARS-CoV-2 infection in COVID-19 patients with downregulated expression of receptor tyrosine kinase ERBB4.

Biomarkers can be used as part of a personalized medicine paradigm to customize treatment to the specific disease characteristics of an individual patient. It can also be used to better understand disease mechanisms and to identify novel disease targets. In the present study, the highly downregulated gene ERBB4 was selected as a drug target and Wortmannin was repurposed as candidate drug to control SARS-CoV-2 infection. Further, this study provides insights on the possible personalized therapeutics for emerging COVID-19. This project contains the following underlying data:

• List of selected differentially expressed coronavirus infected host genes for protein-protein interaction network construction

• List of protein-protein interaction subnetworks

• List of Walktrap modules and potential drug targets "Downregulation of ERBB4 inhibits regular action namely alveolarization, morphogenesis, and AEC2 differentiation" AEC2 or ACE2? It looks like a typing error made in Figure 9 as well as the text. Otherwise, I could not find information on the AEC2 protein.

Is the work clearly and accurately presented and does it cite the current literature? Yes

Is the study design appropriate and is the work technically sound? Yes

Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes

Coronaviruses in Avian Species -Review with Focus on Epidemiology and Diagnosis in Wild Birds

PubMed Abstract | Publisher Full Text | Free Full Text

Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event

Epidemiologic clues to SARS origin in China

PubMed Abstract | Publisher Full Text | Free Full Text

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China

A Novel Coronavirus from Patients with Pneumonia in China

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The Architecture of SARS-CoV-2 Transcriptome

Respiratory Syncytial Virus-Inducible BCL-3 Expression Antagonizes the STAT/IRF and NF-kappaB Signaling Pathways by Inducing Histone Deacetylase 1 Recruitment to the Interleukin-8 Promoter

Expression profile of immune response genes in patients with severe acute respiratory syndrome

Bcl3 prevents acute inflammatory lung injury in mice by restraining emergency granulopoiesis

PubMed Abstract | Publisher Full Text | Free Full Text

SARS coronavirus protein 7a interacts with human Ap4A-hydrolase

Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors

PubMed Abstract | Publisher Full Text | Free Full Text 72

Viruses exploit the function of epidermal growth factor receptor

The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?

PubMed Abstract | Publisher Full Text | Free Full Text

Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication

Activation of C-Type Lectin Receptor and (RIG)-I-Like Receptors Contributes to Proinflammatory Response in Middle East Respiratory Syndrome Coronavirus-Infected Macrophages

PubMed Abstract | Publisher Full Text | Free Full Text

Subversion of cell signaling by pathogens

An overview of hedgehog signaling in fibrosis

Protein-protein docking: From interaction to interactome

PubMed Abstract | Publisher Full Text | Free Full Text

The epidermal growth factor receptor: from development to tumorigenesis

Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor

Coronaviruses induce entryindependent, continuous macropinocytosis

Defining macropinocytosis

Virus entry by macropinocytosis

Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α

PubMed Abstract | Publisher Full Text | Free Full Text

Rac-mediated macropinocytosis of extracellular protein promotes glucose independence in non-small cell lung cancer. Cancers (Basel)

Emerging evidence of signalling roles for PI(3,4)P 2 in class I and II PI3K-regulated pathways

Crossroads of PI3K and Rac pathways

PubMed Abstract | Publisher Full Text | Free Full Text

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Wortmannin, PI3K/Akt signaling pathway inhibitor, attenuates thyroid injury associated with severe acute pancreatitis in rats

Wortmannin targeting phosphatidylinositol 3-kinase suppresses angiogenic factors in shear-stressed endothelial cells

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase

The reno-protective effect of a phosphoinositide 3-kinase inhibitor wortmannin on streptozotocin-induced proteinuric renal disease rats

Datasets for SARS-CoV-2 drug target and candidate drug identification [Data set

The authors are grateful to the Concordia International, GPU-accelerated Graham server of Compute Canada for high-performance computer facilities during this study.

Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, Jefferson, AR, USA Accept for indexing in the current form.Competing Interests: No competing interests were disclosed.

Reviewer Report 20 April 2021 https://doi.org/10.5256/f1000research.55646.r83072 © 2021 Beste T. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Department of Bioengineering, Marmara University, Istanbul, Turkey I enjoyed reading the article. Methods are applied precisely and sound reproducible. Results and Discussion parts are written well and well-organized. There are minor comments that need to be addressed.In the DEG list, there is no information about the expression of the ACE2 receptor which is not only an enzyme but also a functional receptor on cell surfaces through which SARS-CoV-2 enters the host cells and is highly expressed in the heart, kidneys, and lungs and shed into the plasma. However, it is not a DEG on your list. Maybe, it is better to provide a complete list and the readers can see the results about other genes as well.1.

No competing interests were disclosed. Several reports have been reported that ACE2 is one of the key proteins involved in viral entry and it shows interaction with viral protein. In this from the PPI analysis it was noticed that the expression of ACE2 after CoV is not shown in figure 2 . How was ACE2 expression not in the PPI interaction analysis?2.The authors have mentioned that the miRNA data set of differentially expressed CoV-HGs was retrieved for this study, but in the analysis PDT, it was mentioned as SARS-CoV-2, to make it clear.

Based on the protein-protein affinity the authors have concluded ERBB4 has high binding affinity and also it was taken for molecular simulation studies, but in the table 3 it was noticed that KLHL12 has more or less similar binding affinity and also has more binding affinity with MLpro than ERBB4, on what basis have the authors selected ERBB4 as a drug target for further studies?

Are all the source data underlying the results available to ensure full reproducibility? Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. 

Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, Jefferson, AR, USAThe authors put a great effect to identify the potent target and candidate drugs for COVID-19 applying biological networks and structural modeling approaches. The authors should address the below comments before the indexing of this paper:Minor revision: In the introduction, Ref. 16, the authors should mention the authors' name. 1.In methods, data collection, the authors should be clear whether they selected all CoV infected samples or only CoV2 infected samples? 2.In Figure 1 , SARS-CoV means 1 and 2 or only 2? 3.Any particular reason for the authors setting the 303K in molecular dynamics simulations? 4.

Are all the source data underlying the results available to ensure full reproducibility? Yes

Competing Interests: No competing interests were disclosed.Reviewer Expertise: Cheminformatics, Endocrine disrupting chemicals I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Thanks for your suggestion. The author name is included in the text as follows----A recent systematic review by 16 Kermali and his colleagues showed the increased level of biomarkers such as C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, D-dimer, cardiac troponin, and renal biomarkers (urea and creatinine) were higher, and low level of lymphocytes and platelet count were recorded in severe complicated COVID-19 patients than non-severe COVID-19 patients' plasma and infected lung tissues.

In methods, data collection, the authors should be clear whether they selected all CoV infected samples or only CoV2 infected samples? Author Response 2: Thanks for the question. All the selected studies contain control and CoV-infected human lung epithelial cells samples. In earlier days the inadequate information of the CoV-2 genomic datasets in Public databases (i.e. NCBI), the authors have selected CoV samples (i.e. CoV-1 genomic information is more than 96% similar to CoV-2). Figure 1 , SARS-CoV means 1 and 2 or only 2? Author Response 3: Thanks for the key question. The initial drug targets were identified from the SARS-CoV-1 whole-genome datasets. Then, the targets verified and validated with RBD-spike receptor binding domain; 3cLpro-3C-like protease; N pro-nucleocapsid protein of SARS-CoV-2 using protein-protein docking. The protein-protein docking results confirm molecular interaction of the identified drug targets with proteins of SARS-CoV-2. Thus, the first box of Figure 1 , represents the SARS-CoV or SARS-CoV-1.

Any particular reason for the authors setting the 303K in molecular dynamics simulations? Author Response 4: Thanks for the key question. Yes, most computational and experimental studies have focused on room temperature (298K to 303K). The MD simulation input file preparation using the Charmm-gui web-interface was set at 303K as a room temperature (Jo et al., 2008 and Lee et al., 2016). Thus, the authors followed the same.

The benefits of publishing with F1000Research:Your article is published within days, with no editorial bias • You can publish traditional articles, null/negative results, case reports, data notes and more • The peer review process is transparent and collaborative • Your article is indexed in PubMed after passing peer review • Dedicated customer support at every stage • For pre-submission enquiries, contact research@f1000.com